Orthocell Limited (ASX:OCC)

Market Cap	217.05M -29.9%
Revenue (ttm)	9.33M +23.7%
Net Income	-12.48M
EPS	-0.05
Shares Out	271.31M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	771,899
Average Volume	431,713
Open	0.7150
Previous Close	0.7250
Day's Range	0.7050 - 0.8000
52-Week Range	0.7000 - 1.7000
Beta	-0.32
RSI	47.75
Earnings Date	May 22, 2026

About Orthocell

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally. It offers Ortho Autologous Chondrocyte Implantation, a cartilage cell therapy for treatment of articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental applications; and Remplir, a collagen scaffold used in peripheral nerve repair. The company ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: OCC

Financial Performance

In fiscal year 2025, Orthocell's revenue was 7.55 million, an increase of 42.05% compared to the previous year's 5.32 million. Losses were -8.57 million, 19.3% more than in 2024.